AutoImmune announces market launch of Colloral for RA patients
PASADENA, CAL., Feb. 18, 2003 -- AutoImmune Inc. announced that its joint venture with Deseret Laboratories International has begun direct sales of Colloral, a product for the nutritional support of patients with rheumatoid arthritis.
Robert C. Bishop, Ph.D., Chairman of the Board and Chief Executive Officer, said, "Colloral has undergone extensive clinical testing which demonstrated its unique formulation of undenatured Type II collegen to be remarkably safe and of substantial benefit to a large number of patients."
All of the development work on Colloral was done under IND's by AutoImmune and its collaborators who originally anticipated marketing the product as a pharmaceutical. The company transitioned the product to the nutritional supplement category by filing a "Notice of New Dietary Ingredient" with the FDA.
AutoImmune is a biopharmaceutical company involved in the development of a new class of mucosally administered therapies for the treatment of autoimmune and cell-mediated inflammatory diseases and conditions.
Source: AutoImmune Inc. www.autoimmuneinc.com
Posted: February 2003